On February 19, 2023, Abbott, a leading medical and health company in the world, signed a strategic cooperation memorandum with China Medical Devices Co., Ltd., a highly specialized medical device industry chain platform in China, which is affiliated to Sinopharm Holdings. The two sides will give full play to their respective advantages in leading technology, service network, etc., promote comprehensive strategic cooperation around five major fields, including distribution business, logistics platform, after-sales service, digitalization, and medical education, enhance the accessibility of cutting-edge life technology and smart medical solutions in China, such as diagnosis, cardiovascular, diabetes management, and better provide high-quality services for Chinese patients and medical institutions, We will promote the high-quality development of China's medical and health undertakings and help build a "healthy China".

▲ The signing ceremony was held at Abbott's global first integrated customer experience center for the diagnosis industry in Shanghai, Abbott Chuangyue Center. Chen Ying, the global vice president of Abbott's core diagnosis (the seventh from the left in the rear row), Yu Qingming, the chairman of Sinopharm Holdings and the secretary of the Party Committee (the seventh from the right in the rear row), and others attended and witnessed the signing of the cooperation. Qiu Jianping, General Manager of Abbott Rapid Diagnostics in Greater China, and Zhang Wei, General Manager of Sinopharm and Deputy Secretary of the Party Committee signed the contract on behalf of both parties.